Favorable intermediate-risk prostate cancer is a less aggressive form of intermediate-risk disease with a good long-term prognosis. It is defined by the presence of only one of the following risk factors:

-PSA between 10–20 ng/mL,

-Gleason score 3+4=7 (Grade Group 2), or

-Clinical stage T2b–T2c

To be considered favorable, the cancer must also meet these criteria:

-Less than 50% of biopsy cores involved

-No Gleason pattern 4+3 or higher

-No high-risk features (e.g., PSA >20, Grade Group ≥4, or stage T3 or above)

With appropriate monitoring or treatment, patients in this category have a low risk of progression, metastasis, or death from prostate cancer over the next 10–15 years.